Understanding the structures and functions is essential to designing an antibody for a specific goal. Research into developing deep learning models which can help to predict these structures is a fascinating, ever-evolving topic. Deep learning is a subset of machine learning based on stacked artificial neural network layers, in which processing is used to extract increasingly higher-level features from affine transformation and non-linear activation function data.1
DeepH3 is a deep learning model that predicts inter-residue distances and orientations from antibody heavy and light chain sequence. These result in distributions which are then converted to geometric representations and used to discriminate between decoy structures and predict new antibody hypervariable complementarity-determining region (CDR) H3 loops de novo.2
These CDR H3 loops are necessary for antigen binding, and they possess high conformational diversity even if there is high sequence similarity.3 Due to this, CDR-H3 modeling has much fewer constraints than the other five of six CDRs (H1, H2, L1, L2, and L3), which means identifying high-quality H3 templates can be a harder job, with DeepH3 models being very valuable.
Another example of a deep learning method for antibody structure is DeepAb, which predicts accurate antibody FV structures from sequence. There are two steps to Ruffolo et al.’s (2022) process, with the first using a deep residual convolutional network to predict FV structure. Secondly, they use a quick Rosetta-based protocol to realize the structure from the predictions of the network. This method can also be used to model single-domain (VHH) antibodies.4
At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Gao, W., Mahajan, S. P., Sulam, J., & Gray, J. J. (2020). Deep Learning in Protein Structural Modeling and Design. Patterns, 1(9), 100142. https://doi.org/10.1016/J.PATTER.2020.100142
Ruffolo, J. A., Guerra, C., Mahajan, S. P., Sulam, J., & Gray, J. J. (2020). Geometric potentials from deep learning improve prediction of CDR H3 loop structures. Bioinformatics, 36(Supplement_1), i268–i275. https://doi.org/10.1093/bioinformatics/btaa457
Kim, J., McFee, M., Fang, Q., Abdin, O., & Kim, P. M. (2023). Computational and artificial intelligence-based methods for antibody development. Trends in Pharmacological Sciences, 44(3), 175–189. https://doi.org/10.1016/J.TIPS.2022.12.005
Ruffolo, J. A., Sulam, J., & Gray, J. J. (2022). Antibody structure prediction using interpretable deep learning. Patterns, 3(2), 100406. https://doi.org/10.1016/J.PATTER.2021.100406
The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.
Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.
Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.
Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.